LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has granted inducement awards to seven newly hired employees as a means to attract ...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced ...

LANGHORNE, Pa., March 26, 2025--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it ...

Savara (SVRA) “announced encore presentations of top-line data from the pivotal, Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP will ...

As of December 31, 2024, the company had cash, cash equivalents and short-term investments of $196.3M. “Completing submission of the BLA is an ...

SAVARA ($SVRA) is expected to release its quarterly earnings data on Wednesday, April 2nd after market close, per Finnhub. Analysts are expecting revenue of $0 and ...

The latest price target for Savara (NASDAQ:SVRA) was reported by HC Wainwright & Co. on March 28, 2025. The analyst firm set a price target for $6.00 expecting SVRA to rise to within 12 months (a ...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to seven new employees. On April 9 ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement ...